SYNTHETIC BIOLOGY MEETS PRECISION MEDICINE: DRUG REPURPOSING FOR BLOOD CANCER PRECISION MEDICINE

Objective: Optimizing Drug discovery and Translation is one of the key tracks in Global Challenges Annual meeting 2019 and is the critical factor in achieving UN Sustainable Development Goals 3 Good Health and Well Being. WHO reports Cancer is the second leading cause of death globally. The aim of t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Deepak Balaji Thimiri Govindaraj Thimiri Govindaraj
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/de68135673bb4413a69896a5b727da38
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de68135673bb4413a69896a5b727da38
record_format	dspace
spelling	oai:doaj.org-article:de68135673bb4413a69896a5b727da382021-11-10T04:35:15ZSYNTHETIC BIOLOGY MEETS PRECISION MEDICINE: DRUG REPURPOSING FOR BLOOD CANCER PRECISION MEDICINE2531-137910.1016/j.htct.2021.10.1022https://doaj.org/article/de68135673bb4413a69896a5b727da382021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S253113792101169Xhttps://doaj.org/toc/2531-1379Objective: Optimizing Drug discovery and Translation is one of the key tracks in Global Challenges Annual meeting 2019 and is the critical factor in achieving UN Sustainable Development Goals 3 Good Health and Well Being. WHO reports Cancer is the second leading cause of death globally. The aim of the proposal is to establish robust drug screening platform which can identify drugs and drug combinations that are effective in precision medicine for relapsed individual South African Leukemia patients. Methodology: Here, cancer cell will be either directly analyzed using high-throughput drug screening or single cell drug screening will be performed using flow cytometry /microfluidics to provide datasets on drug sensitivity for individual patientsI. WP1: Establishing the culture setting for CLL/MM and high-throughput drug screening on CLL/MM.II. WP2: “Signaling pathway-only” limited drug screening for CLL/MMIII. WP3: Establishing setting for Precision Microfluidics-driven single cell drug screening; Results: Expected Results are using full-library drug screening results, we will identify effective drugs and drug combinations that inhibit cancer cell proliferation either through cytostatic or cytotoxic effects. These results will provide the basis for identifying effective drug combinations using our predictive analytics, which will be packaged as preclinical information for a precision clinical trial. Thus, we would establish cutting-edge platform that can handle blood cancer and also solid tumor. Conclusion: Using this pipeline, we aim to identify drug combinations that can overcome relapse stage and ultimately provide tailored-specific therapy options for Cancer patients. Our intention is to develop technologies that provide clinically relevant drug combinations information to oncologists within a timeframe of 7 days. The development and validation of the screening pipeline will incorporate the first CSIR platforms for cancer translational research with respect to identifying effective cancer drugs.Deepak Balaji Thimiri Govindaraj Thimiri GovindarajElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S37-S38 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Deepak Balaji Thimiri Govindaraj Thimiri Govindaraj SYNTHETIC BIOLOGY MEETS PRECISION MEDICINE: DRUG REPURPOSING FOR BLOOD CANCER PRECISION MEDICINE
description	Objective: Optimizing Drug discovery and Translation is one of the key tracks in Global Challenges Annual meeting 2019 and is the critical factor in achieving UN Sustainable Development Goals 3 Good Health and Well Being. WHO reports Cancer is the second leading cause of death globally. The aim of the proposal is to establish robust drug screening platform which can identify drugs and drug combinations that are effective in precision medicine for relapsed individual South African Leukemia patients. Methodology: Here, cancer cell will be either directly analyzed using high-throughput drug screening or single cell drug screening will be performed using flow cytometry /microfluidics to provide datasets on drug sensitivity for individual patientsI. WP1: Establishing the culture setting for CLL/MM and high-throughput drug screening on CLL/MM.II. WP2: “Signaling pathway-only” limited drug screening for CLL/MMIII. WP3: Establishing setting for Precision Microfluidics-driven single cell drug screening; Results: Expected Results are using full-library drug screening results, we will identify effective drugs and drug combinations that inhibit cancer cell proliferation either through cytostatic or cytotoxic effects. These results will provide the basis for identifying effective drug combinations using our predictive analytics, which will be packaged as preclinical information for a precision clinical trial. Thus, we would establish cutting-edge platform that can handle blood cancer and also solid tumor. Conclusion: Using this pipeline, we aim to identify drug combinations that can overcome relapse stage and ultimately provide tailored-specific therapy options for Cancer patients. Our intention is to develop technologies that provide clinically relevant drug combinations information to oncologists within a timeframe of 7 days. The development and validation of the screening pipeline will incorporate the first CSIR platforms for cancer translational research with respect to identifying effective cancer drugs.
format	article
author	Deepak Balaji Thimiri Govindaraj Thimiri Govindaraj
author_facet	Deepak Balaji Thimiri Govindaraj Thimiri Govindaraj
author_sort	Deepak Balaji Thimiri Govindaraj Thimiri Govindaraj
title	SYNTHETIC BIOLOGY MEETS PRECISION MEDICINE: DRUG REPURPOSING FOR BLOOD CANCER PRECISION MEDICINE
title_short	SYNTHETIC BIOLOGY MEETS PRECISION MEDICINE: DRUG REPURPOSING FOR BLOOD CANCER PRECISION MEDICINE
title_full	SYNTHETIC BIOLOGY MEETS PRECISION MEDICINE: DRUG REPURPOSING FOR BLOOD CANCER PRECISION MEDICINE
title_fullStr	SYNTHETIC BIOLOGY MEETS PRECISION MEDICINE: DRUG REPURPOSING FOR BLOOD CANCER PRECISION MEDICINE
title_full_unstemmed	SYNTHETIC BIOLOGY MEETS PRECISION MEDICINE: DRUG REPURPOSING FOR BLOOD CANCER PRECISION MEDICINE
title_sort	synthetic biology meets precision medicine: drug repurposing for blood cancer precision medicine
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/de68135673bb4413a69896a5b727da38
work_keys_str_mv	AT deepakbalajithimirigovindarajthimirigovindaraj syntheticbiologymeetsprecisionmedicinedrugrepurposingforbloodcancerprecisionmedicine
_version_	1718440606121852928

SYNTHETIC BIOLOGY MEETS PRECISION MEDICINE: DRUG REPURPOSING FOR BLOOD CANCER PRECISION MEDICINE

Ejemplares similares